$ARVN

Saik Andrew sold $46K of ARVN

Saik Andrew (Chief Financial Officer) sold 5,696 shares of ARVINAS, INC. (ARVN) at $8.16 on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Saik Andrew
Published Jun 24, 2026, 9:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ARVN
Neutral
high confidence
Mentioned
$ARVN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARVNNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CFO on 2026-06-24, with a stated pre-arranged 10b5-1 plan, suggesting limited informational content beyond routine compliance/compensation activity.

02

Market read

Primarily a sentiment/positioning datapoint; unlikely to change valuation without additional fundamental news.

03

What to watch

Traders may over-weight small insider sales; the more actionable signal would be any concurrent insider buys, changes in guidance, or operational/regulatory catalysts (none mentioned here).

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-24 (after-hours) for an insider sale executed the same day.

Background

The article is an SEC Form 4 insider transaction disclosure for ARVINAS, Inc. (ARVN).

Company-level read

Ticker impact

$ARVNNeutralHigh confidence
Context

ARVIN’s CFO Saik Andrew sold 5,696 shares in an open-market transaction on 2026-06-24 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan; the disclosed size ($46.5K) is typically not material enough to drive fundamentals.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • ARVINAS, INC.

    Public company whose CFO filed the Form 4 insider sale disclosure.

  • Saik Andrew

    Chief Financial Officer who sold 5,696 shares on 2026-06-24 under a 10b5-1 plan.

Related articles

$ARVNMedAI 8/10

Why is Arvinas stock surging today?

Arvinas shares rose 13.2% after the company reported Q2 2026 results before the open. EPS was $2.58 versus a forecast loss of $0.38, and revenue was $249.7 million versus $58.61 million expected, including licensing and milestone items tied to VEPPANU and Rigel. Management cited VEPPANU approval, upcoming Phase 1 data, and a cash runway into H2 2028.

$ARVNMed

ARVINAS, INC. (ARVN): Results of Operations and Financial Condition

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfull

$GLUEMedAI 9/10

Molecular glue is shaping up to be the next billion-dollar cancer breakthrough

Bloomberg reports that Revolution Medicines’ daraxonrasib, a “molecular glue” drug, doubled median survival in aggressive pancreatic cancer from 6.7 to 13.2 months, with full phase 3 results expected at a Chicago conference. The success has spurred dealmaking and partnerships, including Monte Rosa’s potential $10B+ pacts with Novartis and Roche and J&J’s $3.05B Halda acquisition.